The oncology-focused clinical-stage biopharmaceutical company, Calithera Biosciences Inc. (CALA) has been trodden down since its IPO. Falling by over 83.84% last year, 2022 has been
On February 25, Calithera Biosciences Inc. (CALA) stock added 14.78% during the regular session. There was no official announcement or SEC filing from the company
Calithera Biosciences, Inc. (CALA) is a leading biotherapeutics company focused on the development of drugs used to treat cancers. One of the lead product candidates
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.